JAK Inhibitor Polymorphs for Stable Pharmaceutical Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of knowledge on the crystal forms of the JAK class of non-receptor tyrosine kinase inhibitor 2-(3-(3-amino-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidin-4-yl)azetidin-3-yl)acetonitrile, which limits its pharmaceutical development and application.
Innovation Solution
The development of crystalline forms I, II, III, IV, and V of the inhibitor, characterized by specific X-ray powder diffraction patterns and thermal properties, along with a preparation method suitable for industrial production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no crystal forms are developed for the JAK inhibitor compound, then the compound cannot be effectively used in pharmaceutical applications, but developing crystal forms requires extensive research and characterization work
Solution Approach 1:
The patent performs preliminary crystal form development and characterization work before pharmaceutical application. Multiple crystal forms (I-V) are prepared and characterized in advance, with their XRD patterns, thermal properties, and stability profiles established beforehand to enable future pharmaceutical use without requiring additional characterization work.
Solution Approach 2:
The patent develops multiple crystal forms with different physical and chemical parameters. Each crystal form has distinct XRD peak positions, melting points, and stability characteristics. By changing the crystallization conditions and obtaining different polymorphs, the patent provides options with optimized parameters for various pharmaceutical applications.
2Adaptability or versatility
If multiple crystal forms are developed and characterized, then stability and solubility profiles are obtained for pharmaceutical formulations, but the complexity of characterization and validation increases
Solution Approach 1:
The patent segments the crystal form characterization into distinct, manageable components for each polymorph. Each crystal form (I-V) is characterized separately with its own XRD pattern, thermal properties, and stability profile. This segmentation allows systematic evaluation and selection of the most suitable crystal form for specific pharmaceutical formulations.
Solution Approach 2:
The patent uses X-ray powder diffraction (XRD) and differential scanning calorimetry (DSC) to characterize crystal forms, replacing complex mechanical or visual inspection methods. These analytical techniques provide objective, quantifiable data about crystal structure, purity, and thermal properties, simplifying the characterization process.
3Productivity
If crystal forms are not studied and characterized, then pharmaceutical development is limited, but studying and characterizing crystal forms requires additional time and resources
Solution Approach 1:
The patent performs crystal form development and characterization as preliminary work before pharmaceutical development. By establishing the stability and solubility profiles of multiple crystal forms in advance, the patent eliminates the need for future crystal form research during pharmaceutical development, thereby improving productivity.
Solution Approach 2:
The patent studies phase transitions between different crystal forms to understand their stability relationships. By identifying which crystal forms are thermodynamically stable under different conditions, the patent can predict which forms will persist during storage and processing, reducing the need for long-term stability testing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms provide stability and solubility profiles essential for pharmaceutical formulations, enabling the inhibitor's use in treating autoimmune diseases.
Implementation Method 1
The X-ray powder diffraction pattern of Form I has characteristic peaks at the following 2θ positions: 5.17, 5.55, 6.30, 8.67, 10.34, 15.96, 19.06, 19.75, 20.39, and 21.42
Implementation Method 2
The X-ray powder diffraction pattern of Form I has characteristic peaks at the following 2θ positions
Implementation Method 3
Form IV melts at 224±3°C, and its DSC thermogram is shown in FIG. 7
Implementation Method 4
Form IV melts at 224±3°C
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present application relates to a polymorph of 2-(3-(3-amino-4-(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidin-4-yl)azetidin-3-yl)acetonitrile compound of formula (I) and a pharmaceutical use thereof.